We are live on ! Find out more
IPHA

Innate Pharma
IPHA

6 hedge funds and large institutions have $6.65M invested in Innate Pharma in 2020 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.5% less ownership

Funds ownership: 3.62% → 2.12% (-1.5%)

14% less funds holding

Funds holding: 7 → 6 (-1)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

67% less capital invested

Capital invested by funds: $20.3M → $6.65M (-$13.7M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$28.7K

Top Sellers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
-$3.87M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.42M
3
Morgan Stanley
Morgan Stanley
New York
-$61.7K

IPHA Hedge Fund Activity: Q3 2020 in Review

6 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2020, worth a combined $6.65M — down 67% from $20.3M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of IPHA and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Wellington Management Group, adding an estimated $28.7K. The largest seller was Rubric Capital Management (New York), cutting an estimated $3.87M.

  • 6 institutional investors held Innate Pharma (IPHA) as of Q3 2020, down from 7 in Q2 2020.
  • Funds reported $6.65M of Innate Pharma stock for Q3 2020, down 67% quarter-over-quarter.
  • 0 funds opened new Innate Pharma positions in Q3 2020 and 1 closed out, a net change of -1 holder.
  • The largest Innate Pharma buyer in Q3 2020 was Wellington Management Group, an estimated $28.7K added.
  • The largest Innate Pharma seller in Q3 2020 was Rubric Capital Management (New York), an estimated $3.87M sold.

Based on aggregated 13F filings for Q3 2020.